Відмінності між версіями «Title Loaded From File»
м |
м |
||
| Рядок 1: | Рядок 1: | ||
| − | + | A retrospective analysis of the ten patients was performed. Results:? The anatomical distribution of the osteosarcomas was as follows: lower extremities (n?=?3), upper extremities (n?=?2), breast (n?=?2), lung (n?=?1), cheek (n?=?1) and retroperitoneum (n?=?1). Nine patients initially underwent resection of the primary mass. One patient, who received six cycles of adjuvant doxorubicin and cisplatin chemotherapy was alive in remission at 42.6?months. One patient with postoperative radiotherapy after curative surgery was alive in remission at 6.2?months. However, all three patients who received curative resection but no postoperative radiotherapy or chemotherapy died of the disease at 10.7, 11.1 and 15.6?months after surgery. The median time to failure was only 4.4?months (95% CI, 0.6, 8.2?months) and the median survival time of all patients was only 11.1?months (95% CI, 5.6, 16.6?months). At the time of [http://www.selleckchem.com/products/sch772984.html SCH772984 cost] analysis, seven patients were dead and all died of the disease recurrence. Conclusion:? EOO should be treated as a soft tissue sarcoma with aggressive behavior and multimodality treatment should be actively sought to improve treatment outcome. The impact of adjuvant chemotherapy on survival of EOO needs further investigation. ""In early stage breast cancer chemotherapy relative dose intensity (RDI) of [http://en.wikipedia.org/wiki/Ritonavir Ritonavir] and risk factors contributing to RDI reduction, as well as comparing survival outcomes. A retrospective analysis of 308 patients treated with adjuvant chemotherapy for early stage breast cancer at the Macarthur Cancer Centre was undertaken, with an overall RDI calculated for each patient. The study analysed reasons for reductions in RDI as well as predictive factors for reduced RDI and overall and disease-free survival. Mean RDI was 92%. Of the participants, 17% had an RDI less than 85%, 55% received 100% RDI. Hematological toxicity, infection and patient choice were the most common reasons for RDI reduction. Body surface area capping (BSA) was the [http://www.selleckchem.com/products/dabrafenib-gsk2118436.html Dabrafenib research buy] most common cause of initial dose reduction. Obesity, increasing body mass index and age ��65 years were risk factors for RDI reduction. Disease-free and overall survival were reduced with RDI? | |
Версія за 22:57, 24 листопада 2016
A retrospective analysis of the ten patients was performed. Results:? The anatomical distribution of the osteosarcomas was as follows: lower extremities (n?=?3), upper extremities (n?=?2), breast (n?=?2), lung (n?=?1), cheek (n?=?1) and retroperitoneum (n?=?1). Nine patients initially underwent resection of the primary mass. One patient, who received six cycles of adjuvant doxorubicin and cisplatin chemotherapy was alive in remission at 42.6?months. One patient with postoperative radiotherapy after curative surgery was alive in remission at 6.2?months. However, all three patients who received curative resection but no postoperative radiotherapy or chemotherapy died of the disease at 10.7, 11.1 and 15.6?months after surgery. The median time to failure was only 4.4?months (95% CI, 0.6, 8.2?months) and the median survival time of all patients was only 11.1?months (95% CI, 5.6, 16.6?months). At the time of SCH772984 cost analysis, seven patients were dead and all died of the disease recurrence. Conclusion:? EOO should be treated as a soft tissue sarcoma with aggressive behavior and multimodality treatment should be actively sought to improve treatment outcome. The impact of adjuvant chemotherapy on survival of EOO needs further investigation. ""In early stage breast cancer chemotherapy relative dose intensity (RDI) of Ritonavir and risk factors contributing to RDI reduction, as well as comparing survival outcomes. A retrospective analysis of 308 patients treated with adjuvant chemotherapy for early stage breast cancer at the Macarthur Cancer Centre was undertaken, with an overall RDI calculated for each patient. The study analysed reasons for reductions in RDI as well as predictive factors for reduced RDI and overall and disease-free survival. Mean RDI was 92%. Of the participants, 17% had an RDI less than 85%, 55% received 100% RDI. Hematological toxicity, infection and patient choice were the most common reasons for RDI reduction. Body surface area capping (BSA) was the Dabrafenib research buy most common cause of initial dose reduction. Obesity, increasing body mass index and age ��65 years were risk factors for RDI reduction. Disease-free and overall survival were reduced with RDI?
